Restenosis remains the main limitation of interventional cardiology. Restenosis is an important target for gene therapy since it is frequent (30% of patients), costly (estimated $2 billion annually), refractory to all pharmacological therapies, and related, at least in part, to smooth muscle cell proliferation which is an inviting target for antiproliferative molecular strategies. Because cell division is ultimately controlled by intranuclear events, the protein product of genes selected for their antiproliferative effects usually remains inside the cells. Consequently, the transfer of growth-inhibitory genes needs to be efficient-i.e., involve a large proportion of smooth muscle cells populating the angioplasty site. To date, adenoviral vectors are, by far, the most efficient vectors to perform in vivo arterial gene delivery. These vectors, as well as others, have been recently used to demonstrate that therapeutic genes encoding cytolytic (thymidine kinase) or cytostatic (hypophosphorylatable retinoblastoma protein, endothelial nitric oxide synthase, gax. etc.) products successfully inhibit smooth muscle cell proliferation and related intimal hyperplasia. Despite substantial progress, major technical issues remain to be addressed before gene therapy is applied to clinical restenosis. First-generation recombinant adenoviruses evoke both cellular and humoral immune responses leading to local toxicity and transient gene expression. Moreover, the low efficiency of gene transfer to atherosclerotic arteries may further impair the biological effect of antiproliferative genes. Finally, restenosis is a multifactorial phenomenon in which intimal hyperplasia plays an important but not exclusive role. Prevention of constrictive remodeling should also be taken into account in an integrated genetic strategy to prevent restenosis.
Introduction
The possibility of transferring foreign DNA into arterial wall cells has brought new insights into the pathophysiology of arterial disease and holds considerable promise as a therapeutic tool [l-3] . When transferred into vascular cells at a specific site, the transgene (i.e., the foreign DNA sequences) is expressed locally, resulting in prolonged and progressive production of the recombinant protein encoded by the transgene at that specific site. The hope is that local production of the transgene product will translate into meaningful biological effects and, ultimately, therapeutic benefit. Theoretically, this pharmacokinetic pattern may be a major advantage of gene therapy over conventional pharmacological therapy for arterial disease in that: (1) the high systemic doses necessary to achieve high local drug concentrations are likely to be poorly tolerated; and (2) most methods used for local delivery of recombinant proteins or drugs fail to maintain high local protein concentrations for prolonged periods.
Pioneered by Nabel [4] , the field of arterial gene transfer has evolved at a rapid pace during the past 5 years. Local delivery catheters are now available which allow percutaneous gene transfer to be performed safely at the time of angioplasty [5] . Progress in recombinant DNA technology has led to the design of new vectors [6] able to transfer (transduce) DNA with a relatively high efficiency to endothelial as well as vascular smooth muscle cells.
Most of the research on arterial gene therapy has focused on prevention of restenosis following coronary angioplasty [l-3] . Restenosis is an important target for gene therapy for several reasons. First, it is a frequent (30-500/c of patients) and costly (estimated $2 billion annually in the US) complication of balloon angioplasty and/or related techniques. Second, it has proved refractory to all pharmacological therapies [7-91. Third, smooth muscle cell proliferation-a key factor in the pathogenesis of restenosis-is an inviting target for antiproliferative molecular strategies.
This review will briefly summarize current knowledge on arterial gene transfer, with emphasis on the advantages and limitations of recombinant adenoviral vectors, and on the potential applications to the problem of restenosis.
Ex vivo versus in vivo arterial gene transfer
Two different approaches have been developed to introduce foreign DNA into the arterial wall (Fig. 1) . The first approach, referred to as 'ex vivo (or indirect) gene transfer', involves removal of vascular cells, transduction of these cells ex vivo, and then reintroduction of the modified cells into the vessel wall. Ex vivo gene transfer has been used to seed endothelium-denuded arteries [ 10,111, prosthetic vascular grafts 1121, vein grafts 1131, and stents [ 13-151 with genetically modified endothelial or smooth muscle cells. An advantage of ex vivo gene transfer is that a high percentage of cells are successfully transduced in the well-controlled environment of in vitro transfection, thus optimizing the efficiency of gene transfer. Clinical application of ex vivo gene therapy, however, is limited by the surgical hazard related to cell sampling, as well as the costly and time-consuming procedures required for ex vivo transduction. In contrast, in the second approach, referred to as 'in vivo (or direct) gene transfer', the transgene is directly introduced into the vessel wall during a one-step, clinically-applicable procedure. For these reasons, there is a consensus that arterial gene therapy should be based on in vivo delivery of the therapeutic gene [2] . As recently A B 000 DNA 000 t 1 DNA0 000 1 000 t t 0-o o-0 000 000 depicted by Leclerc and Isner [16] , strategies aimed at introducing foreign DNA into the arterial wall in live animals involve a vector of gene transfer (the 'bullet') to facilitate the cellular uptake of the transgene, a macrodelivery system (the 'gun') to transport the foreign gene to the arterial target site, and a molecular mechanism (the 'target') with which the product of the transgene will ultimately interact.
Vectors for arterial gene transfer
The issue that has dominated the development of arterial gene therapy is transduction efficiency, which conventionally indicated the percentage of cells within the segment of artery exposed to the transgene that show evidence of transgene expression. Since most cells do not naturally incorporate foreign DNA, strategies for arterial gene transfer have generally relied on augmenters of cellular DNA uptake (vectors). However, even when DNA has been successfully introduced into a cell, the likelihood of gene expression remains uncertain because the transgene has to escape lysosomal degradation in the cytoplasm and be transferred into the nucleus for transcription of mRNA, which in turn is exported to the cytoplasm for translation and/or post-translational modification of the protein product. Transduction efficiency represents the final index of this complex regulatory sequence. Certain features of the protein product determine how efficient gene transfer must be to achieve an intended biological effect. For genes encoding proteins that remain inside cells, a high percentage of cells must be transduced to yield a biological response. By contrast, genes encoding proteins flanked with a signal sequence that permits active secretion may overcome the handicap of inefficient transduction via a paracrine effect: abundant protein secretion from even a few transduced cells may be sufficient to achieve local concentrations of protein that are physiologically relevant [ 171. Transduction efficiency, however, remains a major criterion for selection of the appropriate technique to perform arterial gene transfer. Consequently, the development of efficient viral as well as nonviral vectors suitable for gene delivery in the vasculature has been a major focus of recent research [6] .
Retroriral r,ectors have been initially used for arterial gene transfer [4,10,1 I] . Interest for retroviral-mediated gene transfer arose from studies showing that these vectors were able to stably transduce various cell lines, including hepatocytes or human hematopoietic cells. An attractive feature of retroviral vectors, which explains the long-lasting expression of transgenes achieved using these vectors, is their ability to integrate their genome into the genome of target cells. Retroviral vectors currently used for gene therapy are derived from the Moloney murine leukemia virus by deletion of the structure genes gag, pal and em, which inactivates the replication machinery of these vec-tom, and their replacement by the gene of interest [181. In their pioneering study, Nabel and co-workers used a retroviral vector expressing the P-galactosidase reporter gene to transduce porcine iliac arteries in vivo [4] . However, transduction efficiency reported in this study, and in subsequent studies using similar vectors [ 191, was disappointingly low ( < 1 / 1000 transduced cell). Several features of retroviral vectors contribute to their poor efficiency for in vivo gene transfer: (1) target cell replication is required for retroviral integration, whereas the rate of cell proliferation in the arterial wall, even following stimulation by balloon angioplasty, does not exceed a few percent [20, 21] ; (2) it is unclear whether vascular cells possess the specific receptor to amphotropic retroviruses, which has not been characterized yet; (3) retroviral particles are rapidly inactivated in vivo via a complement-mediated process; and finally, (4) attempts to produce the high titer (> lo6 particles/ml) retroviral stocks required for efficient gene transfer have failed.
During the past 3 years, the advent of adenouiral vectors opened new avenues for clinical application of arterial gene transfer [l] . The adenoviral genome is composed of a 36-kb, double-stranded, linear DNA which is divided into 4 'early' regions (El to E4) and a late transcription unit which is alternately spliced to generate 5 distinct families of 'late' mRNAs [22] . The switch from early to late gene expression takes place approximately 7 h after infection. Proteins encoded by the El region activate most other viral transcription units either directly or indirectly, and as such are essential for adenoviral replication. Several characteristics of adenoviral vectors suggest that they might be appropriate vehicles for human gene therapies in general , and arterial gene therapy in particular [l-3] . Indeed, recombinant adenoviruses can be ren- (1) The recombinant adenoviral vector (in this example, a serotype 5 recombinant adenovirus: Ad51 fiber protein binds to its specific receptor at the cell surface: (2) Ad5 is internalized into an endosome vesicle; (3) acidification of endosomes containing adenoviral particles results in endosomolysis, thus adenoviral genome escapes degradation by lysosoma1 enzymes; (4) the transgene is released into the cytoplasm and transferred to the nucleus; (5) the transgene is transcribed into a messenger RNA (mRNA) which is transferred to the cytoplasm; (6) the mRNA is translated into the specific gene product. dered defective for replication, and therefore incapable of establishing a productive infection, by deleting the early sequence El from their genome; they can be produced at high titers (up to 10" particles/ml); they accommodate relatively large cDNA inserts (up to 7.5 kb); they mediate efficient gene transfer regardless of the proliferative state of the target cell (Fig. 2) ; they provide for transient expression of recombinant genes since the viral DNA does not integrate into the host genome; finally, the extrachromosomal location of the viral DNA alleviates concerns regarding the risk of proto-oncogene activation following chromosomal integration inherent in integrative viruses (i.e., retroviruses).
Recent investigations have focused on the feasibility of adenoviral-based arterial gene transfer. In these studies, El -deleted recombinant adenoviral vectors, the so-called 'first-generation adenoviral vectors', expressing various reporter genes (such as nuclear-specific P-galactosidase or luciferase) driven by strong viral promoters were locally infused at a specific arterial site using either an intraoperative route [30-341 or a percutaneous approach [35--401 . These studies clearly demonstrated the ability of adenoviral vectors to transfer DNA to a high percentage of vascular cells. In normal arteries, gene transfer is exclusively localized in the endothelial layer (Fig. 3) where transgene expression can be found in as much as 100% of endothelial cells [30, 34, 36, 38] . When the endothelial layer has been removed by balloon-abrasion or angioplasty, intense medial transduction occurs (Fig. 4) ; in this case, approximately 10 to 30% of medial smooth muscle cells are transduced-i.e., a lOOO-to lOOOO-fold higher efficiency than that previously reported using retroviral vectors [3 l-33,35,37,38,40] .
However, several limitations associated with the use of first-generation adenoviral vectors arose during the course of these studies and have tempered the initial enthusiasm for adenovirus-mediated arterial gene transfer. Transfection efficiency achieved using adenoviral vectors, although higher than that reported with any other vector, still remains to be improved, especially in the setting of gene transfer to severely atherosclerotic arteries [40] (Fig. 5 ). Several methods have been used to optimize adenovirusbased arterial gene transfer, including use of highly concentrated viral preparations [33] and protracted incubation times 1411. These methods, however, may induce tissue toxicity as well as ischemia. Alternatively, we demonstrated that polymers which facilitate adenovirus penetration into smooth muscle cells in vitro [42] , as well as proteolytic enzymes, could be added to adenoviral solutions to increase transfection efficiency in vivo with no additional side-effects [43, 44] .
Another concern is that first-generation El-deleted adenoviral vectors evoke tissue toxicity (Fig. 6 ) due to residual viral protein expression and viral replication, which has been implicated in the inflammatory cell-and T-lymphocyte-mediated immune reaction observed after adenoviral- Endothelial gene transfer. Adenoviral vectors expressing a nuclear P-galactosidase reporter gene were locally delivered into rabbi t double-balloon catheter. In this model, the endothelial layer remains intact. Three days following gene transfer, P-galactosidase d by histochemical staining of arterial sections with the specific chromagen X-gal. which turns blue in presence of P-galactos ene expression is found exclusively in the endothelium (blue nuclei). Nearly 10071 of endothelial cells are transduced. Hem .staining. L = lumen: E = endothelium: M = media: A = adventitia. (L.J. Feldman, personal work.) t iliac arteries expression is idase activity. ratoxylin-eosin ,rteries using a ivity in medial lumen: M = based gene transfer [33, 45, 46] , and may explain the poor clinical tolerance reported in previous clinical trials of adenoviral-mediated gene therapy [47] . In addition, the immune response appears to be an important mechanism explaining the transient nature of gene expression (generally < 3 weeks) observed after adenoviral-based gene delivery to immunocompetent adult animals [3 1,38,40] . Repeated adenovirus administration may not be a suitable method for obtaining more protracted expression since subsequent exposures lead to antibody-mediated reduction in gene expression [48, 49] . Altogether, these observations provide a rationale for the improvement of adenovirusmediated gene transfer technology. One approach would be to manipulate the host immune system to abrogate the cellular immune response. This could be achieved by performing a neonatal administration of the first-generation adenoviral vector, thus inducing tolerance of the recipient to viral antigens, or by subjecting immune-competent recipients to immunosuppression. Both approaches have received experimental support [28, 50, 51] . Low-efficiency of adenoviral-mediated gene transfer to atherosclerotic vs. normal arteries. Adenoviral vectors expressing a nuclear (.3-galactosidase gene were delivered into iliac arteries of normal and atherosclerotic rabbits. Three days following gene transfer, transduction efficiency, measured using (A) chemiluminescent (nuclear p-galactosidase activity/mg protein) as well as (B) morphometric (% transduced neointimal and medial cells) analyses, is significantly reduced in atherosclerotic arteries. P-gal = P-galactosidase; * P = 0.02; * * P < 0.001. (Adapted from Feldman et al. [40] , with permission of the authors.)
of adenoviral vectors to express immunogenic viral proteins by introducing additional functional blocks, other than the El deletion, into the vector genome. Insertion of a temperature-sensitive mutation into the E2A region [5 1 I or further deletion of the B4 region 1521 of El-deleted adenoviral vectors may result in prolonged gene expression and reduced inflammatory cell infiltration. These 'second-' and 'third-generation' adenoviral constructs, respectively, await testing in animal models of arterial gene transfer. In the case of restenosis, however, the molecular mechanisms which are involved in cell proliferation as well as cell migration, the critical steps of lesion formation, are initiated immediately (a few minutes) and culminate early (a few days) following arterial injury, at least in the rat model [53] . Indeed, it has been demonstrated that interventions that inhibit smooth muscle cell proliferation and/or migration during this early period prevent neointimal growth 2 weeks following balloon injury [54] . Therefore, the transient expression of therapeutic genes provided by current adenoviral vectors may not be a limitation to anti-restenosis gene therapies. Safety issues associated with the use of viral vectors in a clinical setting have encouraged development of nonviral methods for arterial gene transfer. Direct 'naked-DNA' injection in the arterial wall is a straightforward method of local gene delivery in the vasculature, but results in very low transduction efficiency [55, 56] . The nonviral vectors which have received the most extensive attention so far are cationic Ziposomes. Cationic liposomes are positively charged lipid particles which interact with negatively charged plasmid DNA to form complexes able to fuse with the cell membrane and release the plasmid DNA in the cytoplasm. Approximately 1% of the successfully transferred DNA escapes proteolytic degradation and is transferred into the nucleus where it remains in an extrachromosomal location [57] . Several studies have provided evidence that cationic liposome-mediated arterial gene transfer was feasible in live animals [4, , with no apparent tissue toxicity [61] . Transduction efficiencies reported in these studies, however, were extremely low ( < 1% transduced cells). Although optimization of the DNA/liposome ratio, as well as the proliferative status of the transduced cells, has been shown to significantly improve gene transfer 1581, it is unlikely that cationic liposomes, in their present form, can be used for arterial gene therapy. Recent reports suggest that new liposome formulations may substantially increase endothelial uptake of foreign DNA [62] , which has been confirmed by preliminary studies in which the transgene has been successfully transferred in normal, but not in de-endothelialized, rat carotid arteries [63] .
It is also possible to associate viral and nonviral components to form new families of vectors which may combine advantages of viral and nonviral methods of gene transfer. Molecular conjugates have been designed which incorporate a ligand (transfertin, asialo-orosomucoid) bound to the polycation poly-L-lysine. In this system, poly-L-lysine condenses with DNA, and the ligand binds to its specific receptor at the surface of the target cell, resulting in a receptor-mediated endocytosis of the ligand/poly-Llysine/DNA conjugate [641. To prevent lysosomal degradation of the transgene, inactivated adenoviral particles have been complexed with molecular conjugates, which resulted in improved transfection efficiency [65] . Similar vectors have been used for gene transfer in jugular vein grafts and reportedly produced high-level transgene expression [66] . Finally, several studies suggest that the hemagglutinating virus of Japan (HVJbthe so-called 'Sendai virus'-substantially enhances arterial gene transfer when complexed with liposome/DNA vectors [67] . Although little information is available on the precise composition of HVJ-based vectors, these have been used to transduce antiproliferative antisense oligonucleotides [68] as well as plasmid DNA [69] in injured rat carotid arteries, resulting in successful inhibition of intimal hyperplasia.
Local delivery catheters
Earlier techniques designed to perform arterial gene transfer included those which relied on direct introduction of the transgene in a surgically exposed, isolated arterial segment [30-3259,701. Although this method is likely to optimize the efficiency of gene transfer, the invasive nature of this approach clearly limits its clinical applicability. In their seminal work, Nabel and her colleagues introduced a double-balloon catheter in porcine iliofemoral arteries via a side-branch under direct vision [4] . Sequential inflation of the 2 balloons isolates an arterial segment in which a solution containing retroviral vectors or cationic liposomes is instilled, allowed to incubate, then retrieved before restoration of flow. Recently, new catheter-based delivery devices (Fig. 7) have been designed (see Refs.
[56,7 1,721 for reviews), and different groups have reported entirely percutaneous approaches [35, 36, 38, 40] . Several challenges still remain to be addressed before percutaneous gene delivery can be proposed for clinical applications of arterial gene transfer. Catheter-based, arterial gene transfer carries the risk of systemic dissemination of the transgene [37, 38, 40] . It is likely that site-specificity of gene delivery depends, in part, upon the catheter design used for gene transfer [38] , and intense efforts currently devoted to improving local delivery systems [5] should diminish the risk of extra-arterial transfection. Alternatively, site-specificity of arterial gene transfer may be improved using vascularcell-specific promoter sequences [73,741, or conjugated adenoviral vectors targeted toward the vessel wall by a specific ligand [75] . Another problem is that current local delivery catheters interrupt blood flow during vector incubation and thereby effectively limit the application of percutaneous gene transfer to the coronary vasculature, intimal hyperplasia pre-angioplasty constrictive remodeling since unacceptable myocardial ischemia may result from protracted incubation times. However, perfusion catheters which maintain distal coronary perfusion have been designed for routine angioplasty, and similar devices adapted for endovascular gene transfer are currently under investigation and should alleviate this limitation in the future [76] . Finally, efficient gene delivery may be optimized by further modifications of the delivery system [38] . For example, diffusion of negatively charged DNA through the cell membrane may be facilitated by iontophoresis, a process whereby charged particles are transported across an electrical gradient established by an electrode catheter placed within the arterial lumen [77] .
Gene therapy for restenosis
One of the promising clinical applications of arterial gene therapy is the prevention of restenosis following balloon angioplasty [l-3] . Balloon injury triggers a cascade of complex molecular events which stimulate intimal hyperplasia [78] as well as constrictive remodeling of the vessel wall [79] , leading eventually to recurrent narrowing of the luminal surface within the months following angioplasty (Fig. 8) . It is still debated which of these two mechanisms contributes predominantly to restenosis [3,79- 831. These uncertainties have been recently emphasized by the conflicting results of two preliminary studies 184,851 in which serial intravascular ultrasound imaging was used to measure directly intimal hyperplasia as well as total vessel area (an index of arterial remodeling) following angioplasty. Fig. 9 . Suicide gene therapy. The suicide gene, encoding the herpes simplex virus thymidine kinase (HSVtk), is not toxic per se. HSVtk phosphorylates the prodrug ganciclovir into a toxic compound which integrates into replicating DNA and induces chain termination, leading to cell death.
To better understand the pathophysiology of restenosis, molecular strategies have been designed to genetically reprogram the arterial wall following balloon injury and thereby alter the restenotic process. In contrast with the unexplored biological basis of arterial remodeling [86] , the molecular determinants of intimal hyperplasia have been, at least in part, identified [87] . They involve the release of a host of cytokines and growth factors by platelets, leukocytes and smooth muscle cells, which in turn leads to the synthesis of gene products that stimulate smooth muscle cell migration and proliferation, leading to intimal growth [88] . It was therefore hypothesized that local delivery of an antiproliferative gene at the site of balloon angioplasty may prevent restenosis by substantially reducing intimal hyperplasia [4] . Several groups, including ours, have recently provided evidence that antiproliferative gene therapy prevents neointimal growth in animal models of restenosis (Table 1) .
A first approach, referred to as 'suicide gene' therapy ( Fig. 91 , is to deliver the gene encoding a herpes simplex virus thymidine kinase fHSVtk) in smooth muscle cells populating the angioplasty site. HSVtk per se is not toxic. However, when transfected animals are subsequently treated with the prodrug ganciclovir, a guanosine analog, HSVtk converts ganciclovir into a triphosphorylated metabolite which incorporates into proliferating cell DNA, inducing chain termination and cell death [89] . In the case of restenosis, this strategy has several advantages. First, it is specifically targeted towards proliferating cells-i.e., those cells causing intimal hyperplasia. Second, potential adverse effects related to either overexpression at the angioplasty site or unexpected remote expression of HSVtk gene can be easily controlled by termination of the ganciclovir course. Finally, it has been reported in several animal models of cancer that HSVtk/ganciclovir provides a successful anti-tumor effect, despite only a small fraction of tumor cells expressing HSVtk, a phenomenon called the 'bystander effect' [90] . The bystander effect, which is likely caused by the transfer of phosphorylated ganciclovir from transfected cells to untransduced neighboring cells via gap-junctions, confers susceptibility to ganciclovir of not only transfected smooth muscle cells but also untransduced, proliferating smooth muscle cells in contact with transfected cells. Efficient inhibition of intimal hyperplasia using an adenoviral vector expressing HSVtk (Ad-HSVtk) has been reported in several animal models including the rat carotid artery [91] , the pig iliofemoral artery [92] , and the atherosclerotic rabbit iliofemoral artery [93, 94] . In these carefully controlled studies, Ad-HSVtk was delivered in the target artery immediately [92-941 or 1 week [91] following balloon angioplasty, and a course of ganciclovir was initiated. Three weeks after angioplasty, a significant ( = 40-60%) reduction of intimal mass, measured by the intima/media area ratio or the intimal surface, was observed in nonatherosclerotic [91, 92] as well as atherosclerotic [93, 94] arteries (Fig. 10) . This effect was probably related to inhibition of smooth muscle cell proliferation by HSVtk/ganciclovir, as suggested by a 40-70% reduction in intimal incorporation of 5bromodeoxycytosine [92] , a marker of cell proliferation. Although no quantitative measurement of transfection efficiency was attempted in these studies, the magnitude of intimal growth inhibition achieved using the HSVtk/ganciclovir system appears to be surprisingly higher than the actual percentage of intimal cells expressing HSVtk, especially in those atherosclerotic arteries which are relatively resistant to adenoviral transfection [40] . This apparent discrepancy in vivo might be related to a bystander effect, as it can be inferred from in vitro data showing that as few as 10% of HSVtk-transduced smooth muscle cells confer susceptibility of 100% cultured cells to ganciclovir [92, 94] . One concern is that phosphorylated ganciclovir might exert its toxic effect not only on intimal smooth muscle cells, but also on dividing endothelial cells, thus hampering re-endothelialization of the injured arterial segment. Indeed, Ohno et al. [92] demonstrated that endothelial regrowth following angioplasty and HSVtk delivery was slightly delayed in animals receiving ganciclovir, suggesting an acute endothelial toxicity of HSVtk during the course of ganciclovir with a preserved capacity to regenerate an endothelial layer following discontinuation of ganciclovir.
Recent progress in the understanding of the regulation of the smooth muscle cell cycle has provided alternative approaches to genetic prevention of restenosis, based on the concept that local overexpression of genes encoding specific inhibitors of the cell cycle may ultimately prevent the development of meaningful intimal hyperplasia at the angioplasty site. The first demonstration that intimal hyperplasia can be genetically inhibited was provided by antisense oligonucleotide technology [54, 68] . Although the precise mechanism responsible for inhibition of gene expression by antisense oligonucleotides is not known [95, 96] , it is believed that an oligonucleotide synthesized with a sequence complementary to a specific mRNA sequence will bind to that sequence in the cytoplasm and inhibit translation of the targeted mRNA. Antisense oligonucleotides can also enter the nucleus and inhibit transport of the mRNA into the cytoplasm. A single intraluminal or periadventitial administration of antisense oligonucleotides directed against the cell cycle regulatory genes cdc2-kinase and PCNA [@I, or the proto-oncogenes c-myb [54] and c-mcy [97] significantly reduced neointima formation after balloon injury of the rat carotid artery. Clinical application of antisense strategy to the prevention of restenosis, however, will require us to address several issues [87, 95, 96, 98] , including a reported lack of specificity [99] , low cellular uptake, and instability of antisense oligonucleotides. Design of phosphorotioate-modified oligonucleotides, resistant to enzymatic hydrolysis, has, in part, resolved the latter issue.
An alternative to antisense therapies consists in transferring at the angioplasty site a gene encoding a cytostatic protein. The retinoblastoma protein (Rb), for example, is a potent inhibitor of the cell cycle (Fig. 11) which is constitutively expressed in its unphosphorylated form in quiescent vascular smooth muscle cells [lOOI. When smooth muscle cells are activated by angioplasty, however, Rb is phosphotylated by a cyclin-dependent kinase. Phosphorylated Rb releases transcriptional factors, such as E2F, which transactivate the expression of proto-oncogenes (cmyc, c-myb), cyclin-dependent kinases (cdc21, and the delta-polymerase co-factor PCNA, leading to cell cycle progression to the S-phase and cell proliferation. The protective role of Rb has been recently studied by Chang et al. in 2 animal models of intimal hyperplasia [lOO] . In this study, the authors tested the hypothesis that local overexpression of a mutant Rb gene encoding a nonphosphorylatable Rb product may compensate for phosphorylation of the constitutive Rb protein induced by balloon angioplasty, and thereby inhibit progression of cell cycle through the S-phase. An adenoviral vector expressing the mutant Rb (Ad-ARb) was shown to inhibit smooth muscle cell proliferation in vitro by > 90% without inducing cell death, which distinguishes an Rb-mediated cytostatic effect from HSVtk/ganciclovir-induced cytolytic activity. Moreover, local delivery of Ad-ARb following balloon denudation of the rat carotid artery markedly reduced intimal hyperplasia ( = 40-50%) as well as medial cell proliferation (= 70%). Similar inhibition of intimal hyperplasia was achieved following catheter-based delivery of Ad-ARb immediately after balloon angioplasty in the femoral porcine artery. More recently, Chang et al. reported that the transduction of the gene encoding the cyclin-dependent kinase inhibitor ~21, which is constitutively expressed to inhibit phosphorylation of Rb in quiescent cells, reduces intimal hyperplasia as well [loll. Vasodilatation and cell growth arrest associated with local production of nitric oxide (NO) suggest that NO is a potential candidate for anti-restenotic therapies [ 102, 103] . Indeed, oral administration of L-arginine, the natural precursor of NO, inhibits intimal hyperplasia in the rabbit iliac artery following balloon abrasion [104] . More recently, von der Leyen and co-workers demonstrated that HVJ-mediated local delivery of a cDNA encoding the endothelial form of NO synthase (eNOS)-the enzyme which produces NO while transforming L-arginine into L-citrulline-results in 70% reduction of the neointimal mass in the rat carotid model [69] .
Another candidate for cytostatic gene therapy is the recently cloned homeobox transcription factor gux ( growth arrest homeobox). The regulation of gax is unique among homeobox factors in that it is expressed at relatively high levels in quiescent vascular smooth muscle cells, but is rapidly downregulated when these cells are stimulated to proliferate with mitogens [105] . Furthermore, gax expression is rapidly reduced in rat aorta following acute injury by balloon angioplasty, demonstrating that its downregulation is an early marker of the cell cycle activity associated with the initiation of restenosis [106] . Conversely, recent studies have demonstrated that microinjection of gax protein into vascular smooth muscle cells inhibits serum-induced cell proliferation in vitro (K. Walsh, personal communication). Based on these observations, an adenoviral vector expressing gax was constructed (Ad-gax) and was shown to efficiently inhibit smooth muscle cell growth by blocking the cell cycle in the G, phase [ 1071. To determine the effects of gax expression on restenosis, Ad-gax was instilled into rat carotid arteries in vivo immediately following balloon injury. Fifteen days later, Ad-gax-infected arteries showed a 75% reduction in the intima/media surface ratio. This translated into a 55% reduction in the percentage of luminal narrowing, an index which was not evaluated in previous reports of adenovirus-based gene therapy for restenosis [91, 92, 94, 1001 . Altogether, these data suggest that Ad-gax induces efficient growth arrest of vascular smooth muscle cells and might be subsequently useful in the treatment of restenosis.
Platelet aggregation and adhesion to the injured arterial wall, and subsequent mural thrombus formation as well as local thrombin production, are important sources of mitogenie factors at the site of angioplasty [108, 109] , and play an important role in restenosis [ 1101. Therefore, genetic strategies aimed at inhibiting thrombus formation [ill] may be of interest for application to the issue of restenosis. For example, Zoldhelyi et al. studied the effects of the gene encoding vascular cycle-oxygenase (COX-1) on thrombus formation in angioplasty-injured porcine carotid arteries [ 1121. COX-1 is the rate-limiting enzyme in the synthesis of prostacyclin, a potent antiaggregant and vasorelaxing agent. Adenovirus-mediated transduction of the COX-1 gene resulted in local overexpression of prostacyclin at the site of angioplasty and subsequent reduction of thrombus. Whether this or related strategies can be successfully applied to restenosis remains to be investigated.
Finally, it has been recently reported that local delivery of the endothelium-specific mitogen, vascular endothelial growth factor fVEGF), at the site of arterial injury accelerates re-endothelialization and attenuates intimal thickening [ 1 131. Therefore, it is possible that restoration of a potentially antiproliferative endothelial layer [ 114, 115] can be facilitated by transferring the VEGF gene to the endoluminal surface of the angioplasty site. Successful transfer to the arterial wall of a VEGF-expressing plasmid from the surface of a hydrogel-coated balloon catheter has been previously reported 11161 and could be used for local VEGF gene delivery in the setting of coronary angioplasty. This example illustrates several potential advantages of genetic strategy over protein therapy. First, the prolonged synthesis and local release of VEGF following gene transfer may constitute a more effective means of stimulating endothelium regrowth than a single administration of VEGF protein. Second, relatively inexpensive expression plasmids encoding a secreted form of VEGF can be designed that may ultimately reduce the high costs associated with production of recombinant proteins [117] . As previously mentioned, direct introduction of naked DNA (i.e., DNA with no vehicle) into the arterial wall has been shown to be feasible, although with low efficiency [56] . In the case of VEGF, however, even a low efficiency may prove sufftcient to induce re-endothelialization and inhibit restenosis since the VEGF gene product is in this case secreted, and therefore capable of stimulating endothelial growth via a paracrine effect. Further studies are warranted, however, to investigate whether the favorable effect of VEGF on abluminal endothelial cells is associated with deleterious intraplaque neoangiogenesis that might predispose to plaque hemorrhage.
Future perspectives: From bench to bedside?
The introduction in the field of arterial gene transfer of highly efficient adenoviral vectors expressing antiproliferative genes allows for development of cytolytic as well as cytostatic gene therapies for prevention of restenosis. We should, however, keep in mind the fact that the risk-to-benefit ratio of gene therapy is higher for arterial disease than for other incurable diseases such as cystic fibrosis, Duchenne's muscular dystrophy, or cancer. To increase the expected benefit, efforts should focus on improving transfection efficiency. Indeed, gene transfer protocols which demonstrated successful inhibition of intimal hyperplasia in non-diseased arteries [ lOO,lOl] yielded very high transfection efficiencies ( = 70% transduced smooth muscle cells), which is unlikely to be achieved in severely atherosclerotic human coronary arteries [40] . Should the efficiency issue not be overcome, new therapeutic genes are warranted which evoke a meaningful antiproliferative effect despite low transduction efficiencies, possibly through active secretion of the gene product [ 1131 or a bystander effect [92, 94] . To lower the risk, more specific and safer gene delivery systems should be designed for arterial gene transfer. Specifically, the issue of toxicity of current adenoviral vectors should be resolved by engineering less immunogenic recombinant adenoviruses before adenovirus-mediated gene therapy for restenosis becomes a clinical reality.
Another concern is that restenosis is a multifactorial phenomenon in which intimal hyperplasia plays an important but not exclusive role. A genetic strategy to prevent restenosis should also take into account the remodeling process [83] . Recent findings that proliferation activity and phenotypic modulation following balloon injury involve not only the intima but also, and maybe predominantly, the adventitia, provide new insights into the patbophysiology of arterial remodeling [ 1181. Indeed, proliferation of adventitial fibroblasts and their transformation into myofibroblasts result in adventitial thickening which is likely to contribute to constrictive remodeling and represent a potential target for gene-based anti-restenosis therapies. Alternatively, restoration of the impaired vasodilator tone, which may be achieved by local overexpression of vasorelaxing genes, such as the NO-producing eNOS [69] or the prostacyclin-generating COX-1 [ 1121, should mitigate the remodeling process as well. Finally, endovascular stents significantly reduce the incidence of restenosis at least in part by preventing constrictive remodeling following angioplasty [119, 120] . The recent reports on successful implantation of heparin-coated stents in the coronary arteries [ 12 l] suggest that coated-stents may be of great interest as a local delivery system for therapeutic gene as well. Therefore, an exciting field for future research may be to associate both antiproliferative gene therapy and anti-remodeling stents in an integrated strategy to prevent restenosis. The scope of arterial gene transfer, however, is no longer limited to restenosis. Investigations are underway which test the potential efficacy of gene therapy for therapeutic angiogenesis [3, 117] , stabilization of the vulnerable atherosclerotic plaque [ill] , and prevention of vascular graft disease 131.
